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Background: The effectiveness of reintroduction of oxaliplatin for metastatic colorectal
cancer (mCRC) refractory to both oxaliplatin and irinotecan was previously reported
in a single arm, open-label phase II study (RE-OPEN, Suenaga, 2015). We conducted a
phase I study to determine the maximum tolerated dose (MTD) and the safety of oxali-
patin plus trifluridine/tipiracil (FTD/TPI, also known as TAS-102) in patients with
refractory mCRC (UMIN000015764).
Methods: Three dosages of intravenous oxaliplatin (50, 65 and 85 mg/m2) on days 1
and 15 and a fixed dose of FTD/TPI 35 mg/m2 bid on days 1–5, 15–19 every 4 weeks
were investigated in patients with refractory mCRC by using a 3þ 3 design. Eligible
patients had received prior oxaliplatin-based treatment that achieved a response or sta-
ble disease followed by confirmed disease progression at least 6 months before entering
the study.
Results: 12 patients were enrolled in the study. Characteristics of patients were as fol-
lows: median age, 62 (range, 47–68) years; male/female, 6/6; ECOG PS 0, 75%; number
of prior regimens3, 33.3%; and median oxaliplatin-free interval, 24.3 (range, 6.2–
71.4) months. 3 of 6 patients of the oxaliplatin 85mg/m2 cohort had dose-limiting tox-
icities (DLTs): treatment delay on 2nd cycle8 days due to grade2 neutropenia or
grade 2 AST/ALT increased. No DLTs were observed in the other cohorts. The median
number of treatment cycles was 3 (range, 1–9): 9 patients continued the treatment until
disease progression; and 3 patients discontinued due to toxicity or patient’s refusal. In
safety, grade3 adverse events were neutropenia (n¼ 3), thrombocytopenia (n¼ 1),
anorexia (n¼ 1) and nausea (n¼ 1). There was no evidence of allergic reaction to oxali-
platin and severe peripheral sensory neuropathy.
Conclusions: According to the results of this phase I study, a combination of trifluri-
dine/tipiracil 35 mg/m2 bid on days 1–5, 15–19 and oxaliplatin 85 mg/m2 on days 1 and
15 every 4 weeks could be a candidate for recommended dose of the trifluridine/tipira-
cilþoxaliplatin regimen in patients with refractory mCRC.
Clinical trial identification: UMIN000015764 (release date, 1/12/2014).
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Background: TAS-102 study was shown to have clinical activity in a large population of
Japanese and Western patientswith heavily pretreated metastatic colorectal cancer,
including those whose disease was refractory to fluorouracil.But we know few date of
TAS-102 in daily medical practice. So we assessed efficacy and safety of TAS-102 for
refractory metastatic colorectal cancer.
Methods: We retrospectively reviewed the data of 86 patientswho received TAS-102
treatment in our institution between June2014 and October2017.TAS-102 (with each
dose consisting of 35 mg per square meter) was administered twice daily, 5 days on and
2 days off for 2 weeks, followed by 2 weeksrest period. The regimen was repeated every
4 weeks.
Results: The median age was 69 years (range, 27–87). Performance status of 1 and 2
were 39 and 47 patients. RAS wild and mutant were 39 and 47 patients. Primary tumor
site of right and left were 25 and 61 patients. All patients had received prior chemother-
apy regimens containing a fluoropyrimidine, oxaliplatin, and irinotecan. 41 patients
received 4 or more prior chemotherapy. Response rate and disease control rate of all
were 1% and 24%. Right and left-sided of response rate were 4% and 0%. Right and
left-sided of disease control rate were 32% and 19%. Median PFS was 62 days, right and
left-sided were 55 and 64 days. Median OS was 216 days, right and left-sided were 262
and 200 days. OS was longer than previously reported. 40 patientsreceived subsequent
chemotherapy. Adverse events were mild with 18% of Grade 4 neutropenia and 4% of
Grade 3 febrile neutropenia.
Conclusions: TAS-102 was active and tolerable for heavily treated refractory metastatic
colorectal cancer. There were no significant difference of PFS and OS in primary tumor
site.
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Background: The multikinase inhibitor regorafenib (REG) is currently registered for
the treatment of colorectal cancer (CRC), gastrointestinal stromal tumors (GIST), and
hepatocellular carcinoma. REG exhibits a pH-dependent solubility, and therefore acid
reducing drugs such as proton pump inhibitors (PPIs, e.g. esomeprazole) might reduce
REG absorption by increasing the stomach pH as was shown for many other kinase
inhibitors (van Leeuwen, Lancet Oncol, 2014). We performed a randomized, 3-phase,
cross-over trial to compare the exposure of REG alone to REG with esomeprazole (con-
comitantly or 3 hours prior to REG intake) in CRC and GIST patients.
Methods: Patients were randomized into 2 sequence groups consisting of 3 phases:
REG intake alone, REG with concomitant esomeprazole (for 5 days), and REG 3 hours
preceded by esomeprazole (for 5 days). Pharmacokinetic (PK) blood sampling was per-
formed at the 21th, 49th and 77th day of the trial. All patients were treated with REG
120 mg at steady-state. Primary endpoint was the relative difference (RD) in geometric
means for REG AUC0-24h. A linear mixed model was used to analyze log-transformed
area under the curve (AUC). For multiple testing a Bonferroni correction was applied.
Results: A total of 14 patients were evaluable for the primary endpoint. Exposure
(AUC0-24h) to REG alone was: 55.9 mg*h/mL (CV: 40.3%). For REG with concomitant
esomeprazole or with esomeprazole 3 hours prior AUC0-24h was: 53.7 mg*h/mL (CV:
33.5%) and 53.6 mg*h/mL (CV: 42.6%) respectively. No significant differences were
identified when REG alone was compared to REG with concomitant esomeprazole
(RD: -3.9%, 95% CI: -20.5-16.1%, p¼ 1.0) or REG with esomeprazole 3 hours prior
(RD: -4.1%, 95% CI: -22.8-19.2%, p¼ 1.0). Furthermore, no significant differences
were observed in other PK parameters of REG and its active metabolites M-2 and M-5
(i.e. Cmax, Tmax). Most common adverse events grade 2 were hypertension (71%),
fatigue (43%) and hand foot skin reaction (36%).
Conclusions: The use of esomeprazole concomitantly or 3 hours prior to REG intake
did not alter REG pharmacokinetics. Our results indicate that PPIs like esomeprazole
can be combined with REG without the appearance of a significant drug interaction.
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Legal entity responsible for the study: Erasmus University Medical Center.
Funding: Bayer.
Disclosure: R.H.J. Mathijssen: Research support: Astellas, Bayer, Boehringer
Ingelheim, Cristal Therapeutics, Novartis, Pamgene, Pfizer, Roche Sanofi;
Consultation fees: Novartis, Servier, Travel support: Astellas, Pfizer. All other authors
have declared no conflicts of interest.
abstracts Annals of Oncology
viii158 | Gastrointestinal tumours, colorectal Volume 29 | Supplement 8 | October 2018
This is an Open Access article under the  CC-BY-NC license.-ND
